Caldwell Sutter Capital’s Vaxcyte PCVX Stock Holding History

Caldwell Sutter Capital’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.1K	Hold	432	–	–	0.01%	500
2026 Q1	$25.1K	Hold	432	–	–	0.01%	454
2025 Q4	$19.9K	Hold	432	–	–	0.01%	474
2025 Q3	$15.6K	Hold	432	–	–	0.01%	502
2025 Q2	$14K	Hold	432	–	–	0.01%	500
2025 Q1	$16.3K	Hold	432	–	–	0.01%	492
2024 Q4	$35.4K	Buy	432 +53	+14%	+$5.26K	0.02%	405
2024 Q3	$43.3K	Hold	379	–	–	0.02%	384
2024 Q2	$28.6K	Hold	379	–	–	0.01%	427
2024 Q1	$25.9K	Buy	379 +20	+6%	+$1.39K	0.01%	437
2023 Q4	$22.5K	Hold	359	–	–	0.01%	445
2023 Q3	$18.3K	Hold	359	–	–	0.01%	459
2023 Q2	$17.9K	Buy	+359	New	+$17K	0.01%	459

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Caldwell Sutter Capital's PCVX Position: Q2 2026 in Review

Caldwell Sutter Capital held its Vaxcyte (PCVX) position steady in Q2 2026 at 432 shares worth $25.1K. The position accounts for 0.01% of the portfolio, ranked #500.

Caldwell Sutter Capital first reported a position in PCVX in Q2 2023 and has held it in 13 quarters since. The position peaked at $43.3K in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Caldwell Sutter Capital held 432 shares of Vaxcyte worth $25.1K as of Q2 2026.
Caldwell Sutter Capital left its Vaxcyte share count unchanged in Q2 2026.
Vaxcyte made up 0.01% of Caldwell Sutter Capital's portfolio in Q2 2026, its #500 holding.
Caldwell Sutter Capital first reported a position in Vaxcyte in Q2 2023 and has held it in 13 quarters since.
Caldwell Sutter Capital's Vaxcyte position peaked at $43.3K in Q3 2024.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Caldwell Sutter Capital's 13F filing for Q2 2026, filed 5 Aug 2026.